Safety and Efficacy of Laquinimod Versus Placebo for Relapsing Remitting Multiple Sclerosis

- Multiple Sclerosis
- Completed

Study Title: Safety and Efficacy of OrFemale, Maley Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

Teva Identifier: MS-LAQ-301 | EUDRACT 2007-003226-19

ClinicalTrials.gov Identifier: NCT00509145

Study Status: Completed

Trial Condition(s): Multiple Sclerosis

Interventions: Drug: Laquinimod | Other: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 55 Years

Trial Duration: 12/01/2007 - 12/01/2010

Phase: Phase 3

Study Type

Interventional